Costanza Alciati, Pharma Analyst, GlobalData, commented, Weight regain and reversal of cardiometabolic improvements are a huge limitation for all marketed GLP-1R agonists, not only for Zepbound. Results from the STEP 1 trial extension study investigating changes in body weight and cardiometabolic risk factors upon semaglutide treatment withdrawal show that upon treatment withdrawal at week 68, patients regained 11.6 per cent of body weight by week 120
Researchers found that tattoo ink is taken up by immune cells in the skin
A meta-analysis ( n = 32 studies) has estimated the prevalence of HHV reactivation in hospital-ICU-admitted COVID-19 cases at 38% for HSV, 19% for CMV, 45% for EBV, 18% for HHV-6, 44% for HHV-7, and 19% for HHV-8, respectively 257
Promising results were reported for a newly developed second generation of antiandrogens for castration resistant prostate cancer (CRPC): ASC-J19, enzalutamide (MDV3100), apalutamide (ARN-509), AZD 3514, Compound30 and VPC-3033
The goal is to give you an honest picture so you can decide, with your provider, whether its worth your time
